Amphastar Pharmaceuticals Highlights Baqsimi Milestones, Primatene Growth at Needham Conference [Yahoo! Finance]
Amphastar Pharmaceuticals (AMPH) was downgraded by
Weiss Ratings from "hold (c-)" to "sell (d+)".
Amphastar Pharmaceuticals (AMPH) had its price target lowered by Barclays PLC from $30.00 to $23.00. They now have an "equal weight" rating on the stock.
Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
Amphastar Pharmaceuticals: Why I Like Bull Put Options Strategy Here [Seeking Alpha]